DEF: Brainstorm Cell Therapeutics Seeks Stockholder Approval for Director Elections, Auditor Ratification, and Equity Plan Amendments at 2025 Annual Meeting

Brainstorm Cell Therapeutics is holding its annual stockholder meeting on June 25, 2025, to vote on director elections, auditor ratification, a common stock issuance proposal, and amendments to its equity incentive plans.

Summary

• Brainstorm Cell Therapeutics Inc. will hold its 2025 annual meeting of stockholders virtually on June 25, 2025.
• Stockholders of record as of May 7, 2025, are entitled to vote on several key proposals.
• The proposals include the election of seven directors, ratification of the appointment of Brightman Almagor Zohar & Co. as the independent registered public accounting firm for the fiscal year ending December 31, 2025, and approval of a common stock issuance proposal to comply with Nasdaq Listing Rule 5635(d).
• Additionally, stockholders will vote on amendments to the company's 2014 Stock Incentive Plan and 2014 Global Share Option Plan to increase the shared pool of shares available for issuance by 2,000,000 shares, from 906,666 to 2,906,666 shares.
• The Board of Directors recommends voting FOR all director nominees, FOR the ratification of the accounting firm, FOR the approval of the issuance proposal, and FOR the approval of amendments to the 2014 Plans.
• The proxy materials are available online, and stockholders can vote via the internet, telephone, or mail prior to the meeting, or online during the virtual meeting.

Sentiment

Score: 6

Explanation: The document is neutral in tone, as it primarily outlines the proposals to be voted on at the annual meeting. While there are some positive aspects, such as the board's active role in risk management, there are also negative aspects, such as the company's involvement in litigation and the potential dilutive effect of the common warrant issuance.

Positives

• The Board of Directors is actively engaged in risk management and oversight.
• The company has a Code of Conduct in place for directors, officers, and employees.
• The company has a compensation recovery policy in place.
• The company is committed to providing long-term, equity-based incentives to attract, retain, and motivate key personnel.

Negatives

• The issuance of shares upon exercise of the common warrant will have a dilutive effect on current stockholders.
• The company has been involved in securities litigation.
• The company has been involved in derivative litigation.
• The company has been involved in a breach of contract lawsuit.

Risks

• Failure to obtain stockholder approval for the issuance proposal may discourage future investors.
• The issuance of shares upon exercise of the common warrant will have a dilutive effect on current stockholders.
• Sales of a substantial number of shares of common stock could adversely affect the market price.
• Provisions of the common warrant could discourage an acquisition of the company by a third party.
• If Proposal No. 4 is not approved, the company will not have a share pool with sufficient shares for issuing annual grants to directors and officers and new discretionary equity grants to new and existing employees.

Future Outlook

The company's future success depends, in large part, upon its ability to maintain a competitive position in attracting, retaining and motivating key personnel, including key new hires of senior executives as the Company proceeds toward commercialization.

Management Comments

• On behalf of the Board, we would like to express our appreciation for your continued interest in our company.

Industry Context

The company operates in an extremely competitive environment with respect to the hiring and retention of qualified employees.

Comparison to Industry Standards

• The company's approach to compensation considers the full range of compensation techniques that enables it to compete with its peers to attract and retain key personnel.
• The company has historically obtained data from a number of different sources, including publicly available data describing director compensation in peer companies and survey data collected by an independent compensation consultant to determine how appropriate the current level of compensation for its non-employee directors is.

Management Changes

Corporate Governance

Legal Proceedings

• The company is involved in a securities class action lawsuit in the U.S. District Court for the Southern District of New York.
• The company is involved in derivative action complaints in the United States District Court for the Southern District of New York.
• 3D Communications, LLC filed a lawsuit against the Company in the U.S. District Court for the District of Delaware, captioned 3D Communications, LLC v. Brainstorm Cell Therapeutics, Inc., Case No. 1:24-cv-01286.

Related Party Transactions

• The company has a Research and License Agreement with Ramot, the technology transfer group within Tel Aviv University.
• The company is party to a subscription agreement and related agreements with ACCBT, a company under the control of Mr. Chaim Lebovits, the company's President and Chief Executive Officer.

Stakeholder Impact

• The issuance of shares upon exercise of the common warrant will have a dilutive effect on current stockholders.
• The company's ability to attract, retain, and motivate key personnel is crucial to its future success.
• The outcome of the legal proceedings could have a material impact on the company's financial condition and results of operations.

Next Steps

• Stockholders are encouraged to vote on the proposals outlined in the proxy statement.
• The company will announce preliminary voting results at the Annual Meeting and will publish final results in a Current Report on Form 8-K to be filed with the SEC within four business days following the Annual Meeting.

Key Dates

Keywords

proxy statement, annual meeting, directors, stockholders, Brightman Almagor Zohar, common stock, issuance proposal, stock incentive plan, global share option plan, equity, compensation